Not medical advice. I am a software engineer, not a physician. This page documents my own protocol and the research I read while building it. Talk to a qualified clinician before changing your supplementation, diet or any treatment. Lab reference ranges quoted here vary by laboratory and by individual.
Affiliate disclosure: the iHerb links on this page carry a referral code and pay me a commission if you buy. It does not change your price, and I do not link anything I do not use myself.
The prostate is a walnut-sized gland located below the bladder that produces seminal fluid, nourishing and transporting sperm. It surrounds the urethra, which is why prostate enlargement (BPH) causes urinary symptoms. The prostate is highly androgen-sensitive — its growth and function are driven primarily by dihydrotestosterone (DHT), the most potent androgen. After age 40, the prostate begins to enlarge in most men, a condition called benign prostatic hyperplasia (BPH) that affects approximately 50% of men by age 50 and 80% by age 80.
Prostate cancer is the second most common cancer in men globally. Early detection through PSA testing and awareness of risk factors (family history, age, DHT levels) is critical. The overlap between DHT's role in hair loss and prostate growth means that interventions targeting 5-alpha reductase benefit both conditions simultaneously.
The DHT connection: DHT is 3-5x more potent than testosterone at the androgen receptor. It is produced by 5-alpha reductase (types I and II) from testosterone. In the prostate, DHT drives cellular proliferation leading to BPH. In the scalp, it miniaturizes hair follicles causing androgenetic alopecia. Inhibiting 5-alpha reductase (with saw palmetto or dutasteride) reduces DHT, benefiting both prostate size and hair retention.
Prostate health management centers on controlling DHT-driven growth, monitoring PSA trends, and maintaining a hormonal environment that minimizes cancer risk while preserving androgenic benefits.
Andriole, G. L., et al. (2010). Effect of dutasteride on the risk of prostate cancer (REDUCE trial). N Engl J Med, 362(13), 1192-1202. PubMed 20357281
These supplements target DHT reduction, estrogen metabolism optimization, and prostate-specific micronutrient support. Dutasteride is included as a prescription reference.
| Supplement | Role | Timing | Details |
|---|---|---|---|
| Saw Palmetto (Serenoa repens) | Inhibits 5-alpha reductase types I & II; reduces DHT ~32%; improves urinary symptoms | 320 mg/day standardized extract with meals | Saw Palmetto |
| Zinc (Picolinate) | Accumulates in prostate at 10x other tissues; inhibits 5-AR; pro-apoptotic in cancer cells | 15-30 mg/day with meals (avoid >40 mg/day) | Zinc Picolinate |
| DIM (Diindolylmethane) | Promotes 2-hydroxylation of estrogen; reduces estrogenic stimulation of prostate tissue | 100-200 mg/day with meals | DIM |
| EGCG (Green Tea Extract) | Antioxidant with anti-proliferative effects on prostate cells; may reduce prostate cancer risk through multiple pathways | 400-800 mg/day standardized extract | EGCG Green Tea |
| Dutasteride (Rx) | Prescription 5-ARI; reduces DHT by ~90%; 23% prostate cancer risk reduction (REDUCE trial) | 0.5 mg/day (requires physician prescription and monitoring) | Supplement Stack |
Dutasteride requires medical supervision: While dutasteride provides the strongest DHT reduction (~90%) and has demonstrated prostate cancer risk reduction, it carries risks including decreased libido (3-5%), erectile dysfunction (5-7%), and potential depression. It also lowers PSA by approximately 50%, which must be accounted for when interpreting PSA results (multiply by 2). Always use under physician guidance with regular monitoring.
Prostate health monitoring focuses on PSA trends (not single values), hormonal assessment, and awareness of the DHT-hair-prostate axis.
| Test | What It Measures | Frequency | Details |
|---|---|---|---|
| PSA (Prostate-Specific Antigen) | Protein produced by prostate; elevated in BPH, prostatitis, and prostate cancer; PSA velocity (rate of change) is more informative than single values | Every 12 months (men >40 or with risk factors) | Lab Tests |
| Free Testosterone | Bioavailable testosterone; testosterone-to-DHT ratio helps assess 5-alpha reductase activity | Every 6-12 months | Lab Tests |
| DHT (Dihydrotestosterone) | Most potent androgen; drives prostate growth and hair loss; useful if elevated PSA or hair loss present | Every 12 months (if clinically indicated) | Lab Tests |
PSA velocity matters more than single values: A PSA of 2.5 ng/mL is less concerning if it has been stable for years than a PSA of 1.5 that has doubled in 12 months. PSA velocity >0.75 ng/mL/year is a significant red flag. Establish a baseline PSA at age 40 and track trends annually. Note: ejaculation, cycling, and prostate manipulation can temporarily elevate PSA — abstain for 48 hours before testing.
2026 AUA/SUO guideline update integrates MRI and new biomarkers. The American Urological Association updated its Early Detection of Prostate Cancer guideline in 2025-2026, recommending MRI prior to initial biopsy to increase detection of clinically significant Grade Group 2+ prostate cancer. PSA remains the first-line screening test, but PSA density (PSA divided by prostate volume on MRI) was consistently the strongest predictor of clinically significant disease in MRI-negative or equivocal cases, outperforming total PSA alone. The guidelines also now include blood panels (PHI, 4Kscore) and urine assays (PCA3, SelectMDx, ExoDx EPI) as validated risk stratification tools — not as PSA replacements, but as decision aids to reduce unnecessary biopsies.
Low baseline PSA predicts 20-year safety: risk-adapted screening endorsed. A large biomarker study published in 2025 found that men aged 45-70 with baseline PSA below 1.00 ng/mL had only a 3.3% risk of prostate cancer over 20 years. This validates risk-adapted screening: men with low midlife PSA can safely extend screening intervals, while those with higher or rising PSA should intensify surveillance. The NEJM also published 4-year results of the PSA + MRI screening strategy, confirming that MRI-based targeted biopsy detects more clinically significant cancers while reducing overdiagnosis of indolent disease.